Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This study found that the Bioengineered Exosomal Hair Growth Factors Complex (BEHC™) enhanced human follicle dermal papilla cell proliferation and reduced inflammatory markers in vitro, while significantly decreasing hair shedding and increasing hair density among participants with androgenetic alopecia in an open-label clinical study.

In a murine model of alopecia areata, this study observed that the IL-2 fusion protein HCW9302 helped prevent disease development by expanding regulatory T cells and reducing disease-causing effector T cell infiltrates, suggesting potential for using IL-2 fusion proteins in alopecia areata treatment.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

In this study on mice, researchers observed that dermal white adipose tissue (dWAT) plays a key role in regulating skin inflammation and tissue repair; however, reduced expression of certain cytokines in obese mice may hinder these processes, indicating potential metabolic disruptions in dWAT during inflammation.

In this case-control study, the researchers found no significant association between IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms and alopecia areata susceptibility among the Egyptian population.

IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.

IL-27 may help prevent hair loss in alopecia areata by promoting immunosuppressive T cells.

This study found that 1,25-dihydroxyvitamin D3 promotes hair growth and regeneration in mice by prolonging the anagen phase and counteracting DHT's inhibitory effects, suggesting its potential therapeutic role for androgenetic alopecia.

In this study, thymic stromal lymphopoietin (TSLP) induced IL-4/IL-13 from T cells, prompting sebum secretion and adipose loss, suggesting IL-4/IL-13 may affect skin barrier function in atopic dermatitis.

In a mouse model of alopecia areata, this study found that IL-27 overexpression using an adeno-associated virus protected against disease development, potentially by promoting immunosuppressive T cells and reducing CD8 T cell infiltration into hair follicles.

In this study, researchers observed that a topical gel containing 20% hypoxia mesenchymal stem cell secretome significantly reduced IL-15 and IFN-γ mRNA expression and baldness by 60% in male Wistar rats with fluconazole-related alopecia.

In this study, secretomes from hypoxic mesenchymal stem cells were found to increase PDGF and reduce IL-1β gene expression in rats, potentially offering an effective topical treatment for alopecia caused by long-term fluconazole use.

This study found that IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms do not have a significant association with alopecia areata susceptibility in the Egyptian population.

This study suggests that administering SH-MSCs gel might decrease IL-6 expression and increase TGF-β expression in alopecia-like rats, indicating potential for alopecia therapy.

In this study, topical administration of secretome hypoxia mesenchymal stem cells gel increased IL-10 and decreased TNF-α gene expression in a fluconazole-induced alopecia-like model in rats, with the 40 μL dose having the most significant effect.

In this study, researchers found that ex vivo and in vivo administration of the TYK2 inhibitor BMS-986202 prevented immune privilege collapse and promoted hair regrowth in models of alopecia areata, suggesting this approach may offer a new therapeutic avenue deserving of clinical investigation.

This study found that patients with alopecia areata had significantly lower frequencies of IL-10 producing CD19+CD24hiCD38hi regulatory B cells compared to healthy volunteers, suggesting a potential role for these cells in the autoimmune response seen in the condition.

This study found that dimethyl fumarate improved delayed wound healing in Il36rn-/- mice by reducing neutrophil extracellular trap formation and oxidative stress.

In ex vivo organ culture of human scalp hair follicles, this study found that IL-9 signaling inhibits hair growth, reduces progenitor cell generation, and disrupts immune privilege.

This research explored the roles of various T cell types in chronic alopecia areata, finding that increased severity of lesions and hair loss may be linked to decreased lesional Foxp3+ Tregs, with a notable role for IL-17 and Th17 lymphocytes in the pathological process.

This study suggests that IL-33 promotes hair follicle changes and T cell infiltration in psoriatic mice and humans, contributing to psoriatic alopecia.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This study identified that certain genetic polymorphisms in IL-16 are associated with an increased risk of alopecia areata in an Iraqi population.

This study reported that IL-15 promotes human hair growth and protects hair follicle immune privilege, potentially stabilizing alopecia areata treatment outcomes when selectively stimulating IL-15Rα signaling.

This study found that IL-17 expression was significantly higher in perifollicular fibrosis of active Lichen planopilaris lesions, suggesting that targeting IL-17 could impact the disease's progression.